Researchers combined data from medical databases to look at how often people with dermatitis have an allergy to isothiazolinones. These chemicals are common preservatives found in many consumer products. The team analyzed records from 2000 to 2025 involving more than 1.5 million patients. They wanted to know how widespread these allergies are and whether they matter for patient care.
The study found that about 4.6 percent of patients had an allergy to methylchloroisothiazolinone and methylisothiazolinone. Methylisothiazolinone alone caused allergies in roughly 5.5 percent of cases. Benzisothiazolinone was less common, affecting about 2.1 percent of patients. The researchers also looked at how clinically relevant these allergies were. They found that over 60 percent of the methylchloroisothiazolinone and methylisothiazolinone cases were considered clinically relevant. For methylisothiazolinone alone, 55.6 percent were relevant. Benzisothiazolinone cases were relevant in 35.3 percent of instances.
The authors noted that usage patterns vary greatly by region depending on local rules. They saw a decline in the use of methylisothiazolinone but an increase in benzisothiazolinone. This shift suggests a need for better monitoring of benzisothiazolinone. The study highlights the importance of proactive risk management for these substances after they are on the market. Readers should understand that these chemicals are common triggers for dermatitis patients.
